Selected research
Industry Research
Mycosis Fungoides Therapeutics Industry Research Report 2026
Market perspective
The global Mycosis Fungoides Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Mycosis Fungoides Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Mycosis Fungoides Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Mycosis Fungoides Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Mycosis Fungoides Therapeutics include Kyowa Kirin Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck & Co. Inc., Soligenix Inc., Seattle Genetics Inc., Horizon Therapeutics Plc, Helsinn Healthcare SA and Celgene Corp. and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Mycosis Fungoides Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Mycosis Fungoides Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mycosis Fungoides Therapeutics Market by Company
Kyowa Kirin Co. Ltd.
Takeda Pharmaceutical Co. Ltd.
Eisai Co. Ltd.
Merck & Co. Inc.
Soligenix Inc.
Seattle Genetics Inc.
Horizon Therapeutics Plc
Helsinn Healthcare SA
Celgene Corp.
Azurity Pharmaceuticals Inc.
Mycosis Fungoides Therapeutics Segment by Type
Small Molecules
Biologics
Mycosis Fungoides Therapeutics Segment by Application
Hospital
Clinic
Other
Mycosis Fungoides Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mycosis Fungoides Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mycosis Fungoides Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mycosis Fungoides Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Mycosis Fungoides Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecules
- Biologics
Applications
- Hospital
- Clinic
- Other
Companies covered
- Kyowa Kirin Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Eisai Co. Ltd.
- Merck & Co. Inc.
- Soligenix Inc.
- Seattle Genetics Inc.
- Horizon Therapeutics Plc
- Helsinn Healthcare SA
- Celgene Corp.
- Azurity Pharmaceuticals Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Mycosis Fungoides Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Small Molecules
- 2.2.3 Biologics
- 2.3 Mycosis Fungoides Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Mycosis Fungoides Therapeutics Breakdown Data by Type
- 3.1 Global Mycosis Fungoides Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Mycosis Fungoides Therapeutics Forecasted Market Size by Type (2027-2032)
4 Mycosis Fungoides Therapeutics Breakdown Data by Application
- 4.1 Global Mycosis Fungoides Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Mycosis Fungoides Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Mycosis Fungoides Therapeutics Market Perspective (2021-2032)
- 5.2 Global Mycosis Fungoides Therapeutics Growth Trends by Region
- 5.2.1 Global Mycosis Fungoides Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Mycosis Fungoides Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Mycosis Fungoides Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Mycosis Fungoides Therapeutics Market Dynamics
- 5.3.1 Mycosis Fungoides Therapeutics Industry Trends
- 5.3.2 Mycosis Fungoides Therapeutics Market Drivers
- 5.3.3 Mycosis Fungoides Therapeutics Market Challenges
- 5.3.4 Mycosis Fungoides Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Mycosis Fungoides Therapeutics Players by Revenue
- 6.1.1 Global Top Mycosis Fungoides Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Mycosis Fungoides Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Mycosis Fungoides Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Mycosis Fungoides Therapeutics Head Office and Area Served
- 6.4 Global Mycosis Fungoides Therapeutics Players, Product Type & Application
- 6.5 Global Mycosis Fungoides Therapeutics Manufacturers Established Date
- 6.6 Global Mycosis Fungoides Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 7.2 North America Mycosis Fungoides Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Mycosis Fungoides Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 8.2 Europe Mycosis Fungoides Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Mycosis Fungoides Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Mycosis Fungoides Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Mycosis Fungoides Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 10.2 South America Mycosis Fungoides Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Mycosis Fungoides Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Mycosis Fungoides Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Kyowa Kirin Co. Ltd.
- 12.1.1 Kyowa Kirin Co. Ltd. Company Information
- 12.1.2 Kyowa Kirin Co. Ltd. Business Overview
- 12.1.3 Kyowa Kirin Co. Ltd. Revenue in Mycosis Fungoides Therapeutics Business (2021-2026)
- 12.1.4 Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
- 12.1.5 Kyowa Kirin Co. Ltd. Recent Developments
- 12.2 Takeda Pharmaceutical Co. Ltd.
- 12.2.1 Takeda Pharmaceutical Co. Ltd. Company Information
- 12.2.2 Takeda Pharmaceutical Co. Ltd. Business Overview
- 12.2.3 Takeda Pharmaceutical Co. Ltd. Revenue in Mycosis Fungoides Therapeutics Business (2021-2026)
- 12.2.4 Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
- 12.2.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
- 12.3 Eisai Co. Ltd.
- 12.3.1 Eisai Co. Ltd. Company Information
- 12.3.2 Eisai Co. Ltd. Business Overview
- 12.3.3 Eisai Co. Ltd. Revenue in Mycosis Fungoides Therapeutics Business (2021-2026)
- 12.3.4 Eisai Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
- 12.3.5 Eisai Co. Ltd. Recent Developments
- 12.4 Merck & Co. Inc.
- 12.4.1 Merck & Co. Inc. Company Information
- 12.4.2 Merck & Co. Inc. Business Overview
- 12.4.3 Merck & Co. Inc. Revenue in Mycosis Fungoides Therapeutics Business (2021-2026)
- 12.4.4 Merck & Co. Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 12.4.5 Merck & Co. Inc. Recent Developments
- 12.5 Soligenix Inc.
- 12.5.1 Soligenix Inc. Company Information
- 12.5.2 Soligenix Inc. Business Overview
- 12.5.3 Soligenix Inc. Revenue in Mycosis Fungoides Therapeutics Business (2021-2026)
- 12.5.4 Soligenix Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 12.5.5 Soligenix Inc. Recent Developments
- 12.6 Seattle Genetics Inc.
- 12.6.1 Seattle Genetics Inc. Company Information
- 12.6.2 Seattle Genetics Inc. Business Overview
- 12.6.3 Seattle Genetics Inc. Revenue in Mycosis Fungoides Therapeutics Business (2021-2026)
- 12.6.4 Seattle Genetics Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 12.6.5 Seattle Genetics Inc. Recent Developments
- 12.7 Horizon Therapeutics Plc
- 12.7.1 Horizon Therapeutics Plc Company Information
- 12.7.2 Horizon Therapeutics Plc Business Overview
- 12.7.3 Horizon Therapeutics Plc Revenue in Mycosis Fungoides Therapeutics Business (2021-2026)
- 12.7.4 Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Product Portfolio
- 12.7.5 Horizon Therapeutics Plc Recent Developments
- 12.8 Helsinn Healthcare SA
- 12.8.1 Helsinn Healthcare SA Company Information
- 12.8.2 Helsinn Healthcare SA Business Overview
- 12.8.3 Helsinn Healthcare SA Revenue in Mycosis Fungoides Therapeutics Business (2021-2026)
- 12.8.4 Helsinn Healthcare SA Mycosis Fungoides Therapeutics Product Portfolio
- 12.8.5 Helsinn Healthcare SA Recent Developments
- 12.9 Celgene Corp.
- 12.9.1 Celgene Corp. Company Information
- 12.9.2 Celgene Corp. Business Overview
- 12.9.3 Celgene Corp. Revenue in Mycosis Fungoides Therapeutics Business (2021-2026)
- 12.9.4 Celgene Corp. Mycosis Fungoides Therapeutics Product Portfolio
- 12.9.5 Celgene Corp. Recent Developments
- 12.10 Azurity Pharmaceuticals Inc.
- 12.10.1 Azurity Pharmaceuticals Inc. Company Information
- 12.10.2 Azurity Pharmaceuticals Inc. Business Overview
- 12.10.3 Azurity Pharmaceuticals Inc. Revenue in Mycosis Fungoides Therapeutics Business (2021-2026)
- 12.10.4 Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 12.10.5 Azurity Pharmaceuticals Inc. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst